VTYX - Company ID 0001851194
The table below shows Ventyx Biosciences, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$25.72M | -$47.63M | -$30.92M | -$12.73M | -$3.02M |
| Capital expenditure | $16.00K | $175.00K | $60.00K | $38.00K | - |
| Investing cash flow | $26.41M | $41.77M | -$18.89M | -$16.50M | $1.90M |
| Dividends paid | - | - | - | - | - |
| Stock buybacks | - | - |
Ventyx Biosciences, Inc. reported operating cash flow of -$130.87M for fiscal year 2024. That is up 21.4% from -$166.52M in fiscal 2023. Over the 5 fiscal years shown, operating cash flow declined from -$6.20M (FY 2020) to -$130.87M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Financing cash flow | - | $96.18M | $48.65M | $86.00K | $56.87M |